+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID06485466

Study Comparing TACE Plus Camrelizumab and Apatinib Versus Camrelizumab and Apatinib Alone for Unresectable Liver Cancer

Led by Guohui Xu · Updated on 2026-04-14

101

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Hepatocellular carcinoma HCC is a common and serious form of liver cancer often diagnosed at intermediate or advanced stages when curative treatments are not an option. This trial focuses on patients with initial BCLC-B or BCLC-C stage unresectable HCC, aiming to compare two treatment approaches involving transarterial chemoembolization TACE combined with immune and anti-angiogenic therapies. The study evaluates the safety and effectiveness of TACE plus camrelizumab and apatinib versus camrelizumab plus apatinib alone in this patient population. Participants are randomly assigned to one of two groups. One group receives TACE, which involves delivering chemotherapy drugs directly into the livers blood supply via the femoral artery, followed within one week by camrelizumab intravenously every three weeks and daily oral apatinib. The other group receives only camrelizumab and apatinib at the same doses and schedules. This open-label, multicenter trial is designed to assess these treatments over several months, focusing on progression and survival outcomes. During the study, participants undergo regular assessments including imaging to measure tumor response, laboratory tests to monitor organ function and safety, and clinical evaluations. The primary outcome is progression-free survival up to 24 months, while secondary outcomes include response rates and overall survival up to 48 months. Participants are followed throughout treatment and monitored to evaluate effectiveness and any side effects, with adherence to treatment schedules and safety protocols.

CONDITIONS

Brief Title

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

Research Team

X

Xuegang Yang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here